The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.-
Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Ami Claxton, MS, PhD has joined Ionis Pharmaceuticals, Inc. as Director, Global HEOR Rare Disease Immunology. She will play a critical and significant role as… 
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years…
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…